Eisai's US CEO and Alzheimer's lead Ivan Cheung telegraphs retirement days after Leqembi's full FDA nod

Right after Leqembi's full approval from the U.S. FDA, Eisai’s global Alzheimer’s disease officer is getting ready to hang up his hat.

Ivan Cheung, who also serves as the Japanese pharma’s American CEO, will retire at the end of the month, Eisai said in a Tuesday release. With Cheung headed for the exit, Keisuke Naito—the 34-year-old son of Eisai’s head honcho Haruo Naito—has taken up the lead Alzheimer’s disease mantle, the company added.